EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Successful Treatment of Anti‐Jo‐1 Positive Inflammatory Myopathy With Tofacitinib

Janis Timsans iD, Anna-Mari Hokkanen iD, Joonas Rautavaara iD, Anne Kerola iD, Sanna Huovinen iD, Markku Kauppi iD

Case Reports in Rheumatology · 2026-01 · 2026 (1)

DOI: 10.1155/crrh/6478835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Rheumatology, online erschienen am 03.06.2026. Verfasst von Janis Timsans und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, uta.fi. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic inflammatory myopathies are, in some cases, refractory to all guideline‐based treatments, posing a very difficult challenge in clinical practice. Janus kinase inhibitors are a rather new class of disease‐modifying antirheumatic drugs that are approved for the treatment of rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis, but have been used as an off‐label treatment only in a very limited number of cases in inflammatory myopathies. In this case report, we present a middle‐aged woman with severe muscle weakness and pain attributed to refractory myositis associated with anti‐Jo‐1 antibody. Despite multiple treatment attempts, which included all guideline‐based immunosuppressants, the patient’s condition remained unresponsive. Initiation of tofacitinib therapy resulted in significant clinical improvement, normalization of creatinine kinase levels, and being possible to discontinue glucocorticoids. Our findings highlight the potential efficacy of tofacitinib in refractory inflammatory myopathies, and to our knowledge, our case is the first one to demonstrate the efficacy of a Janus kinase inhibitor in anti‐Jo‐1 positive myopathy without interstitial lung disease.

Autor:innen und Institutionen

  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland, uta.fi.
  • Department of Rheumatology, Päijät-Häme Central Hospital, Wellbeing Services County of Päijät-Häme, Lahti, Finland, phsotey.fi.
  • University of Helsinki, Helsinki, Finland, helsinki.fi.
  • Department of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland, pshp.fi.

ORCID-Profile: Janis Timsans, Anna-Mari Hokkanen, Joonas Rautavaara, Anne Kerola, Sanna Huovinen, Markku Kauppi

Zitieren

APA

Timsans, J., Hokkanen, A. M., Rautavaara, J., Kerola, A., Huovinen, S., & Kauppi, M. (2026). Successful Treatment of Anti‐Jo‐1 Positive Inflammatory Myopathy With Tofacitinib. Case Reports in Rheumatology, 2026(1). https://doi.org/10.1155/crrh/6478835

Vancouver

Timsans J, Hokkanen AM, Rautavaara J, Kerola A, Huovinen S, Kauppi M. Successful Treatment of Anti‐Jo‐1 Positive Inflammatory Myopathy With Tofacitinib. Case Reports in Rheumatology. 2026;2026(1). doi:10.1155/crrh/6478835

BibTeX
@article{Timsans2026,
  author = {Timsans, Janis and Hokkanen, Anna-Mari and Rautavaara, Joonas and Kerola, Anne and Huovinen, Sanna and Kauppi, Markku},
  title = {Successful Treatment of Anti‐Jo‐1 Positive Inflammatory Myopathy With Tofacitinib},
  journal = {Case Reports in Rheumatology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crrh/6478835}
}
Kostenlos starten →